Literature DB >> 7789650

Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes.

P J Beisswenger1, Z Makita, T J Curphey, L L Moore, S Jean, T Brinck-Johnsen, R Bucala, H Vlassara.   

Abstract

Elevated levels of advanced glycosylation end products (AGEs) have been found in multiple tissues in association with diabetic vascular complications and during the microalbuminuric phase of diabetic nephropathy. In this study, we have used an AGE-specific enzyme-linked immunosorbent assay (ELISA) to measure skin AGEs to determine whether elevated levels can be detected before the onset of overt microangiopathy. Subjects with type I diabetes (n = 48) were graded for the degree of nephropathy (normal [23], microalbuminuria [12], or macroalbuminuria [12]) and retinopathy (none [13], background [20], or proliferative [15]). Subgroups with a premicroalbuminuric phase of albumin excretion (< or = 28 mg/24 h, n = 27) or with the earliest stages of retinopathy (n = 27) were identified. A significant increase in tissue AGEs was found as urinary albumin increased during the premicroalbuminuric phase of nephropathy even when the data were adjusted for age and duration of diabetes (P = 0.005). Immunoreactive AGEs also increased as normal renal status advanced to microalbuminuria and macroalbuminuria (P = 0.0001 across groups). Significant elevation of AGEs was also found in association with the earliest stages of clinically evident retinopathy (early background versus minimal grades). In addition, higher AGE levels were found in subjects with proliferative retinopathy when compared with those with less severe retinopathy (P < 0.004 across groups). In contrast, no significant differences were found in tissue AGE levels between groups with or without early retinopathy based on pentosidine or fluorescent AGE measurements, although fluorescent AGEs correlated with albumin excretion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7789650     DOI: 10.2337/diab.44.7.824

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  47 in total

1.  CCN-2 is up-regulated by and mediates effects of matrix bound advanced glycated end-products in human renal mesangial cells.

Authors:  Xiaoyu Wang; Susan V McLennan; Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2011-06-02       Impact factor: 5.782

Review 2.  Prandial glucose regulation in the glucose triad: emerging evidence and insights.

Authors:  Paul Beisswenger; Robert J Heine; Lawrence A Leiter; Alan Moses; Jaakko Tuomilehto
Journal:  Endocrine       Date:  2004-12       Impact factor: 3.633

3.  Effects of advanced glycation end-products on the proliferation and differentiation of osteoblast-like cells.

Authors:  A D McCarthy; S B Etcheverry; L Bruzzone; A M Cortizo
Journal:  Mol Cell Biochem       Date:  1997-05       Impact factor: 3.396

4.  DNA Advanced Glycation End Products (DNA-AGEs) Are Elevated in Urine and Tissue in an Animal Model of Type 2 Diabetes.

Authors:  Richard Jaramillo; Sarah C Shuck; Yin S Chan; Xueli Liu; Steven E Bates; Punnajit P Lim; Daniel Tamae; Sandrine Lacoste; Timothy R O'Connor; John Termini
Journal:  Chem Res Toxicol       Date:  2017-02-03       Impact factor: 3.739

Review 5.  Role of HMGB1 signaling in the inflammatory process in diabetic retinopathy.

Authors:  Jena J Steinle
Journal:  Cell Signal       Date:  2020-06-01       Impact factor: 4.315

6.  Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway.

Authors:  Guihua Zhou; Cai Li; Lu Cai
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

Review 7.  Association of albuminuria and the metabolic syndrome.

Authors:  Kevin Rowley; Kerin O'Dea; James D Best
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

8.  Simple non-invasive assessment of advanced glycation endproduct accumulation.

Authors:  R Meerwaldt; R Graaff; P H N Oomen; T P Links; J J Jager; N L Alderson; S R Thorpe; J W Baynes; R O B Gans; A J Smit
Journal:  Diabetologia       Date:  2004-07-09       Impact factor: 10.122

Review 9.  Advanced glycation end products, oxidative stress and diabetic nephropathy.

Authors:  Sho-Ichi Yamagishi; Takanori Matsui
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

10.  Functional brain connectivity and neurocognitive functioning in patients with long-standing type 1 diabetes with and without microvascular complications: a magnetoencephalography study.

Authors:  Eelco van Duinkerken; Martin Klein; Niki S M Schoonenboom; Roel P L M Hoogma; Annette C Moll; Frank J Snoek; Cornelis J Stam; Michaela Diamant
Journal:  Diabetes       Date:  2009-07-07       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.